The clinical oncology next generation sequencing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Clinical Oncology Next Generation Sequencing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.
The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers –
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market.
Market Trends –
Companies in the clinical oncology next-generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample-to-sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that investigates automating DNA sequencing to better diagnose and treat patients.
The clinical oncology next generation sequencing market covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories
Get an inside scoop of the clinical oncology next generation sequencing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp
Regional Insights –
North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Table of Contents
1. Executive Summary
2. Clinical Oncology Next Generation Sequencing Market Report Structure
3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies
4. Clinical Oncology Next Generation Sequencing Market – Macro Economic Scenario
5. Clinical Oncology Next Generation Sequencing Market Size And Growth
…..
27. Clinical Oncology Next Generation Sequencing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
